SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 8, 2024 /CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will present at the JonesHealthcare Seaside Summit on Monday, July 15, 2024 at 11:00 a.m. PT.
David R. Parkinson, President and Chief Executive Officer, will host the presentation and will also participate in a panel discussion titled "Innovations and Challenges in Prostate Cancer" at 9:00 a.m. PT.
A live webcast of the presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com. Following the event, the webcast will be archived on the ESSA website for 90 days. The panel, "Innovations and Challenges in Prostate Cancer," will not be webcast.
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit www.essaphrma.com, and follow us on X and LinkedIn.
Contacts
ESSA Pharma Inc.
Peter Virsik, Chief Operating Officer
778.331.0962
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors and Media:
Argot Partners
212.600.1902
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.20 |
| Daily Volume: | 0 |
| Market Cap: | US$9.320M |
October 06, 2025 February 11, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
